Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915470 · ClinicalTrials.gov registry record · Phase 2
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
A Phase 2 study of Surgical Site Infection and Staphylococcal Infections, sponsored by Destiny Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT03915470 is a Phase 2 study of Surgical Site Infection and Staphylococcal Infections that has completed, run by Destiny Pharma. The registered enrollment target is 124 participants, below the 563-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03915470, a Phase 2 study of Surgical Site Infection and Staphylococcal Infections, has completed, sponsored by Destiny Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looks at the difference between XF-73 and placebo in reducing the carriage of a bacteria S. aureus in the nose before, during and after heart surgery. Only people who normally have S.aureus in their nose will be enrolled onto the study. This will be confirmed by analysis of a nasal swab (a cotton bud placed in the nose) before entering the study. It is expected 125 people will participate in this study. Participation will be confirmed by analysis of a nasal swab (a cotton bud placed in the nose) before entering the study. XF-73 or placebo will be given 5 times, with an equal chance of participants receiving either XF-73 or placebo. During the hospital stay more nasal swabs will be taken to determine the amount of S.aureus present in the participant's nose. Other tests such as blood samples, blood pressure and an examination of the nose and sense of smell will be performed as part of the safety assessment. After the hospital stay participants will be followed up for 30 days or if a device has been inserted into the body as part of the surgery for 90 days to look at the rates of post-operative infection between the placebo and XF-73 groups. The study will run for about 18 months. During this period, an independent data monitoring committee will review the study to make sure that the balance of benefits and risks of participating in the study does not change.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XF-73
Study Locations (20)
Other
- Ltd Clinic LJ - Kutaisi
- Ltd Israel-Georgia Medical Research Clinic Helsicore - Tbilisi
- Ltd "Open Heart" - Tbilisi
- Ltd Cardiology Clinic Guli - Tbilisi
- Ltd Acad. G.Chapidze Emergency Cardiology Center - Tbilisi
- Ltd Bokhua Memorial Cardiovascular Center - Tbilisi
- Ltd Tbilisi Heart and Vascular Clinic - Tbilisi
- Ltd Clinic Jerarsi - Tbilisi
- Ltd Tbilisi Heart Center - Tbilisi
- JSC Evex Hospitals - Tbilisi
- Clinical Center of Serbia - Belgrade
- Clinic for Cardiac Surgery, Institute for Cardiovascular Disease-Deinje - Belgrade
- Institute for Cardiovascular Disease of Vojvodina - Kamenitz
Florida
- University of Florida - Gainesville
Idaho
- Snake River Research, PLLC - Pocatello
Iowa
- MercyOne Iowa Heart Center - Des Moines
Louisiana
- Ochsner Clinic Foundation - New Orleans
Missouri
- University of Missouri Health Care - Columbia
Texas
- Memorial Hermann - Memorial City Medical Center - Houston
Washington
- CHI Franciscan Research Center - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915470
The ClinicalTrials.gov registry entry for NCT03915470 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 563-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (78% lower). The listed sponsor is Destiny Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Surgical Site Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03915470 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT03915470 about?
NCT03915470 is a clinical study titled "Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection". This study looks at the difference between XF-73 and placebo in reducing the carriage of a bacteria S. aureus in the nose before, during and after heart surgery. Only people who normally have S.aureus in their nose will be enrolled onto the study. This will be confirmed by analysis of a nasal swab (...
What is the current status of trial NCT03915470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2019-08-29. Estimated completion is 2021-03-29.
What conditions does trial NCT03915470 study?
This clinical trial studies the following conditions: Surgical Site Infection, Staphylococcal Infections.
What interventions are being tested in trial NCT03915470?
The interventions under investigation include: Placebo (DRUG), XF-73 (DRUG).
Who is sponsoring clinical trial NCT03915470?
This trial is sponsored by Destiny Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915470 being conducted?
This trial has 20 study locations across Florida, Idaho, Iowa, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Site Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Treatment and Prevalence of P. Acnes
COMPLETED · Phase 2
-
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)
COMPLETED · Phase 2
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections
RECRUITING · Phase 3
-
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
RECRUITING · Phase 4
-
Studying How Outpatient Water affEcts Risks With Drains (SHOWER Study)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.